SCHEMBL14239256

SCHEMBL14239256

CCC(C)c1ccc(N(C)C)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.37
ALDH1A1 P00352 6/20 0.37
TSHR P16473 1/20 0.37
HPGD P15428 2/20 0.36
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HCAR3 P49019 1/20 0.35
RAB9A P51151 4/20 0.35
KMT2A Q03164 2/20 0.35
GBA1 P04062 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
APP P05067 1/20 0.34
NPC1 O15118 3/20 0.33
CYP2C9 P11712 2/20 0.33
LMNA P02545 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14239248 0.83 HRH3 (0.41) ALDH1A1TSHRHPGDUSP2GAA
SCHEMBL14239249 0.80 HCAR3 (0.39) ALDH1A1TSHRHPGDPKMHCAR3
SCHEMBL11990167 0.80 HCAR3 (0.39) ALDH1A1TSHRHPGDUSP2GAA
SCHEMBL12089777 0.80 APP (0.38) KCNH2GAAAPPLMNASMN1; SMN2
SCHEMBL11990206 0.79 GBA1 (0.41) KCNH2ALDH1A1TSHRHCAR3KMT2A
SCHEMBL14238178 0.79 HCAR3 (0.38) ALDH1A1TSHRHPGDPKMHCAR3
SCHEMBL11990178 0.78 TRPV1 (0.39) ALDH1A1TSHRHPGDPKMHCAR3
SCHEMBL24784713 0.77 APP (0.36) KCNH2GAAAPP
SCHEMBL4333553 0.77 ADRB2 (0.39) KCNH2GAAAPP
SCHEMBL3266864 0.77 ESR1 (0.43) ALDH1A1TSHRHPGDUSP2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120309963-A1 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309963-A1 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS MAP3K5, CDK5, MAP4K2 KCNH2 1723/4885ALDH1A1 3982/4885TSHR 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.